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Abstract
Duchenne muscular dystrophy (DMD) is an incurable neuromuscular degenerative disease, caused by a mutation in the
dystrophin gene. Mdx mice recapitulate DMD features. Here we show that injection of wild-type (WT) embryonic stem cells
(ESCs) into mdx blastocysts produces mice with improved pathology and function. A small fraction of WT ESCs incorporates
into the mdx mouse nonuniformly to upregulate protein levels of dystrophin in the skeletal muscle. The chimeric muscle
shows reduced regeneration and restores dystrobrevin, a dystrophin-related protein, in areas with high and with low
dystrophin content. WT ESC injection increases the amount of fat in the chimeras to reach WT levels. ESC injection without
dystrophin does not prevent the appearance of phenotypes in the skeletal muscle or in the fat. Thus, dystrophin supplied
by the ESCs reverses disease in mdx mice globally in a dose-dependent manner.
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Introduction
DMD is an X-linked recessive disorder affecting 1 in 3500
newborn males. DMD is characterized by progressive muscle
weakness associated with necrosis of muscle fibers and fibrosis of
muscle tissue. Patients are usually confined to wheelchairs by age
8–11 years and generally die of respiratory failure by their early
twenties [1,2]. Although several therapeutic venues have been
investigated [3–14], there is currently no cure.
DMD is caused by defects in the dystrophin gene. The full
isoform (427 kD) of dystrophin localizes to the sarcolemma of the
skeletal muscle. Dystrophin forms a complex with other proteins
including dystroglycans, sarcoglycans, dystrobrevin and syntro-
phin called the dystrophin-glycoprotein complex (DGC) [15]. The
DGC provides stability to the membrane and protects the skeletal
muscle from mechanically induced damage. The C terminus of
dystrophin is dispensable, partly because dystrobrevin (a distant
dystrophin-related protein) can substitute for some of the functions
of dystrophin, like binding to syntrophin. Syntrophin is responsible
for localizing neuronal nitric oxide synthase (nNOS) to the
sarcolemma. In the absence of dystrophin, the DGC is unstable
and is destroyed [16–21].
Research on DMD has benefited from the availability of mdx
mice, in which a naturally occurring mutation in exon 23 of the
dystrophin gene abrogates expression of the full-length dystrophin
polypeptide, causing symptoms reminiscent of muscular dystrophy
[22,23]. These mice exhibit moderate signs of skeletal muscle
dystrophy but have nearly normal lifespan. This mild phenotype is
due in part to compensatory upregulation of the dystrophin-
related protein utrophin [24–26]. Previous studies in mice showed
that only a fraction of the muscle must express full-length
dystrophin to confer protection against the development of
muscular dystrophy, as mice with a mosaic pattern of expression
in the skeletal muscle displayed a markedly milder phenotype than
mdx mice, despite the expression of dystrophin in only half the
muscle fibers [27].
In addition to skeletal muscle, the full isoform of dystrophin is
expressed in the cardiac and smooth muscles, and the brain
[28,29]. A short C-terminal isoform of dystrophin (apodystrophin,
Dp71 or non-muscle dystrophin) is widely distributed in various
non-muscle tissues, but Dp71 is not affected in mdx and its
absence does not contribute to muscular dystrophy [24,30].
Although the primary defect in the skeletal muscle is very well
characterized, the relationship between the absence of the protein
dystrophin and the pathogenetic mechanisms of DMD is still
unclear. For example, abnormal vasoregulation in the exercising
muscles of DMD patients and in the mdx muscle contributes to the
vascular and dystrophic phenotypes, and forced expression of
dystrophin in the smooth muscle of mdx mice partially corrects the
phenotype [31,32]. Thus, it appears that nonskeletal muscle full-
length dystrophin plays a corrective role in the disease. This
observation led us to hypothesize that partial restoration of
PLoS ONE | www.plosone.org 1 March 2009 | Volume 4 | Issue 3 | e4759dystrophin in all tissues could uncover novel corrective effects of
dystrophin.
To study global corrections, we injected wild type ESCs into
mdx blastocysts. We created chimeric mice composed by
dystrophin positive ES-derived cells and dystrophin-negative
mdx cells. ESCs incorporated at a low percentage but globally
throughout the chimeric mouse. We report that dystrophin
supplied by WT ESCs not only stabilizes the skeletal muscle in
areas with high dystrophin and in areas with low dystrophin, but
also corrects tissues that are affected in mdx and in DMD outside
of the muscle, such as fat.
Results
We wanted to determine if early injection of ESCs could revert
phenotypes in mdx mice globally. To this end, we injected WT
ROSA26 (R26) LacZ-marked ESCs (WT ESCs) into mdx
blastocysts and examined the resultant mice (WT/mdx chimeras)
at 4 months of age. At 3 weeks of age, the degree of chimerism was
estimated by performing Xgal staining from sections of tail
biopsies. After sacrifice, the degree of chimerism was assessed by
Xgal staining in heart, liver and lung sections. The degree of
chimerism was confirmed by dystrophin staining in heart sections
and by dystrophin detection in western blots with protein extracts
from hearts. Because skeletal muscle is syncytialized, neither Xgal
(b-galactosidase is sarcoplasmic) nor dystrophin staining reflects
the degree of chimerism. Therefore, the degree of chimerism in
skeletal muscle was assessed by semi-quantitative PCR detection of
the LacZ transgene in the R26 locus. Mdx heterozygous females
contain one functional allele (50%) and are non-dystrophic [33].
Thus, we selected WT/mdx chimeras having less than 30% of WT
ESC incorporation (n=9 in the range of 10–30%, n=2 in the
range of 5–10% and n=12 in the range of less than 5%).
WT/mdx mice exhibit improved pathology and skeletal
muscle function
Gross examination indicated that, unlike mdx mice, hindlimb
muscles from WT ESC-injected mice (10–30% incorporation) did
not appear enlarged (data not shown). When suspended by the tail,
chimeric mice straightened their hindlimbs. Histological analysis
of muscles (pectoralis, quadriceps, tibialis anterior [TA]) from 10–
30% WT/mdx mice displayed not more than 30% of central
nucleation (in contrast to 60–90% of central nucleation in mdx or
chimeric muscle with fewer than 5% of ESC incorporation)(Fig 1
and Table 1). In addition, the appearance of necrotic areas,
extensive mononuclear invasion and lack of an organized
architecture in the 5–10% and ,5% chimeric muscle (Fig 1c
and d) and in the mdx muscle (data not shown) was reversed in the
10–30% chimeric muscle (Fig 1b, compare to Fig 1a, Table 1).
Unlike mdx and ,5% chimeric diaphragms, which were thicker
(450–650 mm), contained 12–24 fibers across the width and
displayed greater than 20% of central nucleation, WT or 10–30%
chimeric diaphragms showed no such abnormalities (thickness:
160–250 mm, 5–10 fibers across the width, less than 10% of
central nucleation) (P,0.001)(Fig. 2a–i, k–m, Table 1). The fiber
cross-sectional area (CSA) distribution of WT and 10–30%
chimeric diaphragms co-peaked at 500 mm
2 (mode) and the
values were higher than those of the mdx or ,5% chimeric
diaphragms (300 mm
2 and 400 mm
2 respectively), probably due to
the presence of small caliber, regenerating (,300 mm
2) fibers in
the mdx or ,5% muscles (Fig. 2j and Table 1). Interestingly, all
the chimeric and the mdx diaphragms exhibited a high percentage
of fibers with CSAs greater than 900 mm
2 (26% for 10–30%
chimeras, 56%,5% chimeras and 17% for mdx compared to 6%
for WT)(Fig. 2j), suggesting the presence of hypertrophic fibers in
the chimeric muscles (P,0.05). Indeed, some fibers of ,5%
chimeras exceeded CSAs of 3,000 mm
2. Consistent with histolog-
ical corrections, the extensor digitorum longus (EDL) from 10–
30%, but not from ,5% WT/mdx chimeras exhibited functional
improvement. Stress output (force/cross sectional area) for tetanic
contractions (42.863.6 g/mm
2, n=4) and twitch contractions
(7.060.8 g/mm
2, n=4) from the EDL of 10–30% chimeras but
not from ,5% chimeras (22.262.2 tetanic: g/mm
2; twitch:
4.860.4 g/mm
2, n=4) were comparable to that of WT mice
(tetanic: 46.462.5; twitch: 6.960.7 g/mm
2; n=4), and signifi-
cantly higher from that of mdx mice (tetanic: 20.067.9; twitch:
5.262.0 g/mm
2, n=3). (P,0.05 between 10–30% [or WT]
versus ,5% chimeras [or mdx])(Table 1). Thus, incorporation of
WT ESCs into mdx mice improves skeletal muscle pathology and
function in a dose-dependent manner.
R26 ESC-derived tissues produce b-galactosidase
As expected for a syncytium, the muscle from 10–30% chimeras
contained 50–90% of X-gal stained fibers (Fig. 3 and Table 1),
while other tissues of the same chimeras (liver, heart, brain and
lung) contained less than 30% of X-gal stained cells (Fig. 3b–d and
Table 1) (P,0.001). The diaphragm contained more blue fibers
(20–50% of blue fibers, Table 1) than blue cells from the liver (10–
30% of blue cells, Fig. 3c and Table 1), but less than the
quadriceps, pectoralis or TA (Fig. 3a, i, j, Table 1 and data not
shown). Genomic PCR confirmed the presence of the LacZ allele
in all tissues analyzed (Fig. 3m), indicating widespread incorpo-
ration of ESCs into the mouse chimera. The pattern of X-gal
staining in muscle was non-uniform, with varying intensities. Blue
staining varied from fiber to fiber, and also from different portions
within the same fibers (Fig. 3a and 3i, j, insets). Importantly,
muscle areas with minimal X-gal staining, but surrounded by areas
with high number of blue fibers (Fig. 3j, inset) displayed peripheral
nucleation (Fig. 3k [magnification of white dotted box in 3j]),
indicating no regenerating activity. As expected, non-blue fibers
were more abundant in an animal with 10% than in another with
30% of WT R26 ESCs, with concomitant appearance of a higher
Figure 1. ESC incorporation prevents mononuclear invasion
and central nucleation. a–d, Tibialis anterior (TA) muscle from WT (a),
10–30% WT/mdx (b), 5–10% WT/mdx (c) and ,5% WT/mdx (d) mice
were paraffin sectioned and H&E stained. Magnification of a–d: 2006.
More than 2 animals per group (WT [n=5], 10–30% WT/mdx [n=5], 5–
10% WT/mdx [n=2] and ,5% WT/mdx [n=5]) were analyzed.
doi:10.1371/journal.pone.0004759.g001
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not shown).
Because the skeletal muscle regenerates via activation of
myogenic precursor cells, we wanted to know if these cells were
also derived from ESCs. A fraction of the myogenic cells derived
from chimeric muscle was also Xgal positive (Fig. 3e), and
contracting multinucleated myotubes produced from this prepa-
ration were also blue (Fig. 3f and g). Because the skeletal muscle of
the WT/mdx chimeras displayed a large percentage of Xgal
positive fibers distributed throughout the muscle (spatial expan-
sion), we wanted to know if the spatial expansion of the R26 ESCs
in the muscle required the presence of an mdx component. We
also wanted to determine if this effect appeared during
development or postnatally. To this end, we injected R26 ESCs
into WT blastocysts, and generated WT/WT chimeras. We
stained the embryos with Xgal and examined muscle precursors at
developmental stages E11.5 and at E17.5 (Fig. 3h, inset and 3h).
No preferential staining was observed in the myotomes at E11.5
(where no multinucleation is apparent). However, spatial expan-
sion was observed in the muscle of the E17.5 embryos (where
multinucleation becomes apparent). Thus, expansion of Xgal
staining throughout the muscle occurs at late stages of develop-
ment, and does not require mdx blastocysts as recipient embryos.
Immunofluorescence analysis using a dystrophin antibody
confirmed the observations obtained with X-gal staining: 50–
90% (pectoralis, quadriceps and TA) and 30–70% (diaphragm) of
the 10–30% WT/mdx skeletal fibers were positive for dystrophin
(with varying intensities)(Fig 4b–d and Fig. 5g, j; compare to
Fig. 5a, d). This is in contrast to the low numbers of dystrophin-
positive cardiomyocytes (10–30%) (Fig. 6c, compare to Fig. 6a,
b)(P,0.001) observed in the same 10–30% chimeric animals.
Dystrophin-negative fibers as well as dystrophin-negative cardio-
Table 1. The degree of chimerism correlates with the degree of corrections.
WT chim10–30 chim5–10 chim,5 mdx
Xgal staining (% of cells or skeletal muscle fibers)
heart 0 10–30 ,5 ,50
liver, lung, brain 0 5–30 ,5U D 0
quadriceps 0 50–70 ,5U D 0
pectoralis 0 50–90 10–30 ,50
diaphragm 0 20–50 UD UD 0
Dystrophin (WB, % relative to WT)
heart 100 10–30 5–10 ,50
quadriceps 100 60–100 ,50 0
pectoralis 100 70–100 5–10 0 0
diaphragm 100 30–60 10–15 ,50
Fiber cross-sectional area (mm
2)
diaphragm (mode) 500 500 400 400 300
Central nucleation (%)
quadriceps, TA, pectoralis ,10 10–30 ND 60–90 60–90
diaphragm ,5 ,10 20–40 25–45 20–40
Muscle thickness (mm)
diaphragm 160–180 180–250 540–600 550–650 450–550
Fiber count across width
diaphragm 6–10 5–10 8–13 12–18 18–24
Mononuclear invasion*
dorsal diaphragm, pectoralis, TA 2 ++ +++ ++++++ ++++++
Dystrophin glycoprotein complex (IMF)(dbv-a, synt, nNOS, SG-b)
diaphragm ++++++ ++++++ +++ ++ ++
Sarcolemmal utrophin (IMF)
diaphragm 2 ++ ND ++++++ ++++++
eMHC (IMF, fold increase by microarrays)
diaphragm, pectoralis 2 ++,U C ++++,N D ++++++,N D ++++++,2 4
Mechanical stress (g/mm
2)
EDL (tetanus) 46.462.5** 42.863.6 ND 22.262.2 20.067.9**
EDL (twitch) 6.960.7** 7.060.8 ND 4.860.4 5.262.0**
chim10–30: chimeric mice that incorporated between 10 and 30% of ESCs (n=9); chim5–10 (n=2); chim,5 (n=12); WT (n.10); mdx (n.10).
UC: unchanged; UD: undetectable; ND: not determined; IMF: immunofluorescence.
dbv-a: dystrobrevin-a; syntrophin: synt; neuronal nitric oxide synthase: nNOS; sarcoglycan b:S G - b.
*++low degree; ++++++ high degree.
**WT and mdx twitch and tetanic stress values are unpublished data from A.Wolff’s dissertation (Virginia Polytechnic Institute and State University, 2007).
doi:10.1371/journal.pone.0004759.t001
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and data not shown for cardiomyocytes).
WT/mdx muscle overproduces dystrophin
We determined the degree of ESC incorporation in the WT/mdx
skeletal muscles by quantitating the percentage of DNA containing
the LacZ transgene. To this end, we isolated DNA from skeletal
muscle (and liver) of R26/mdx chimeras. We also isolated DNA
from skeletal muscle (and liver) of R26 mice, which containthe LacZ
transgene in all the nuclei (and from whom the R26 ESCs were
derived), as well as DNA from skeletal muscle (and liver) of WT and
of mdx mice, which contain no LacZ transgene. In skeletal muscle,
most of the DNA comes from the myonuclei. We performed semi-
quantitative PCR with primers that specifically amplify the LacZ
transgene from R26 ESC-derived but notfrom themdx nuclei inthe
chimera. As expected, the degree ofchimerism intheliver ([chimeric
liver/R26 liver]6100) of the chimeric animals was low (5–15%), and
roughly overlaps with the value of b-gal positive cells, which is also
low (5–30%, Table 1). The degree of chimerism in the muscle
([chimeric muscle/R26 muscle]6100) of the 10–30% chimeric
animalswasalsolowat11–19%(Fig7g),butdidnotoverlapwiththe
high percentage of b-gal positive fibers (50–70% in the quadriceps,
Figure 2. WT/mdx chimeric muscle exhibits improved pathology in a dose-dependent manner. a–i, Diaphragms from 4 month-old WT
(a), 10–30% WT/mdx chimeric (b–d), 5–10% WT/mdx chimeric (e–f), less than 5% chimeric WT/mdx (g, h) and an mdx (i) mice were paraffin sectioned
and H&E stained. j–m, fiber size distribution (j), thickness (k), fiber count across the diaphragm width (l) and percentage of central nucleation (m)
measurements. Note that the thickness, the number of fibers across the diaphragm width or the percentage of central nucleation depends on the
percentage of ESCs incorporated. Two or three diaphragm muscles per animal per group (WT [n=3], mdx [n=3], 10–30% WT/mdx [n=3], 5–10% WT/
mdx [n=2] and ,5% WT/mdx [n=3]) were analyzed. At least 200 fibers were analyzed per animal per group for the studies indicated in (j) and (m). 20
measurements of thickness, with the corresponding number of fibers, per animal per group were performed in the studies indicated in (k) and (m).
Magnification of a–i: 1006.
doi:10.1371/journal.pone.0004759.g002
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PLoS ONE | www.plosone.org 4 March 2009 | Volume 4 | Issue 3 | e4759Figure 3. b-galactosidase activity is detected in chimeric tissues. a–d, Xgal (blue) staining of sections of pectoralis muscle (a, longitudinal),
heart (b), liver (c), brain (d, left) and lung (d, right) from 10–30% R26 WT/mdx chimeric mice (4006 for a–c and 2006 for d). a and d: eosin
counterstained; b and c: H&E counterstained. Xgal staining in (d) (brain and lung) was weak and punctuated. e–g, myogenic cells (e) were isolated
from pectoralis muscle of 10–30% R26 WT/mdx chimeric mice, and subjected to differentiation into multinucleated, contracting myotubes (f,
g)(4006). h, E17.5 R26 WT/WT embryos were collected, cryosectioned at the hindlimb level and Xgal/eosin stained (2006). Adjacent sections were
MHC (MF20) immunostained to visualize the developing muscle (not shown). h inset, E11.5 R26 WT/WT embryos were collected, whole mount Xgal
stained, cryosectioned at the thoracic level and myogenin (Myo) immunostained to visualize the myotomes (2006). i, j, insets, Xgal/eosin staining of
pectoralis muscle (transverse) cryosections from 10–30% R26 WT/mdx chimeric mice displaying uniform Xgal (i, inset) and non-uniform Xgal (j, inset)
staining (1006). i, j, H&E staining of areas adjacent to i, j, insets (1006). k is a magnification (4006) of the dotted white box in (j) showing negligible
Xgal staining. l, pectoralis muscles from mdx mice were cryosectioned and H&E stained. Note that while (k) shows peripheral nucleation, (l) shows
central nucleation. m, genomic DNA was isolated from various tissues of 10–30% R26 WT/mdx chimeras and subjected to PCR for b-galactosidase. +:
positive control with DNA from the tail of a R26 WT mouse. 2: negative control with DNA from the tail of a non-R26 WT mouse. Xgal staining
experiments were performed with muscles, heart, liver, lung and brain tissues of all WT/mdx chimeras (n=9 for 10–30%, n=2 for 5–10% and n=12
for ,5% WT/mdx) and percentage of positive fibers are indicated in Table I. Myogenic cells were derived from pectoralis and quadriceps muscles of
two 10–30% chimeras (n=2). LacZ PCR was performed with DNA from two 10–30% chimeras (n=2). Five WT/WT embryos at E11.5 (n=5) and five
WT/WT embryos at E17.5 (n=5) were Xgal stained.
doi:10.1371/journal.pone.0004759.g003
ESC Corrections in Mdx Mice
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This indicates that even though a large percentage of the muscle
fibers contain b-gal activity, there is no preferential homing of R26
ESCs to the skeletal muscle compared to other tissues such as lung,
liver or heart. Thus, all tissues within a WT/mdx animal contain a
similar (low) degree of mosaicism.
To determine if dystrophin protein levels in the chimeric muscle
correlated to the degree of chimerism, we performed western blots
on muscle tissue (pectoralis, diaphragm and quadriceps) from
chimeric mice (Fig. 7). Values relative to dystrophin protein
present in the WT muscle (100%) were obtained by band scanning
and normalized by tubulin according to the formula: dystrophin
chimera/tubulin chimera]/[dystrophin WT/tubulin WT]6100
(Table 1). As expected, in the heart of the 10–30% WT/mdx
chimeras, where no syncytia form, dystrophin levels reached 10–
30% of that seen in WT mice (Table 1 and Fig. 5a). However, in
the quadriceps and pectoralis (and at a lower extent in the
diaphragm) where syncytia develop, dystrophin levels reached 70–
100% (pectoralis), 60–100% (quadriceps) and 30–60% (dia-
phragm) of that seen in WT mice (Table 1, Fig. 7c, e and f for
pectoralis, quadriceps and diaphragm respectively). The observa-
tion that dystrophin levels are elevated in skeletal muscle relative
to heart muscle with comparable extent of chimerism suggests that
WT ESC-derived myonuclei have the ability to overproduce
dystrophin to compensate for the inability of the mdx myonuclei to
produce the protein. A compensatory effect was also observed in
the mdx+/2 mice (mdx heterozygous mice recapitulate DMD
asymptomatic carriers). Because of X-chromosome inactivation,
only half of the cardiomyocytes contain dystrophin (Fig. 6b,
compare to Fig. 6a), whereas all skeletal muscle fibers contain
dystrophin (Fig. 4a, inset). Concordant with this finding, 50% of
the WT level of dystrophin was observed in the heart of the mdx
heterozygous mice, but 100% of WT levels were observed in the
skeletal muscle (Fig. 7b, d). Thus, overproduction of dystrophin
occurs in the skeletal muscle but not in the heart. In addition, since
the mdx+/2 mice have not received ESCs, overproduction of
dystrophin in a chimeric muscle does not require ESC injection.
Using microarray analysis we confirmed previous reports [34]
showing that dystrophin RNA in the skeletal muscle of the mdx
mouse is reduced (Tables 2 and S1), probably because most of the
mutated transcript is inactive and thus destroyed. However,
dystrophin RNA levels in the WT/mdx mice were unchanged
relative to WT mice (Tables 2 and S2), even though WT/mdx
mice contained only 10–30% of WT cells. Thus, elevation of
dystrophin RNA accompanies elevation of dystrophin protein.
WT/mdx muscle shows reduced regeneration
To determine the molecular consequences of incorporation of
WT ESCs into the mdx musculature, we performed microarray
analysis to search for restoration of markers dysregulated in the mdx
muscle. The embryonic isoform of myosin heavy chain (a marker of
regeneration, eMHC, [35]), which was upregulated in the mdx
muscle (Tables 2 and S1), was normalized in the 10–30% WT/mdx
chimeric muscle (Tables 2 and S2). In addition, thymosin-b10 (a
smallactin-binding proteininvolved incytoskeletalremodeling,[36])
and a number of procollagen genes (which are responsible for the
formation of a fibrotic muscle, [37]), were also upregulated in the
mdx muscle, and normalized in the 10–30% WT/mdx chimeric
muscle (Tables 2, S1 and S2). An antibody reactive with eMHC did
not detectareasofregeneratingfibersinthe WTorin10–30%WT/
mdxchimeras(Fig.4a–dand Tables1and S2)evenoutsidetheareas
of dystrophin-positive fibers (within the utrophin-positive areas)
(Fig. 4c and d and Fig. 5j–l). By contrast, eMHC was detected in the
5–10% and the ,5% WT/mdx as well as in the mdx muscle
(Fig. 4e–h, Tables 1 and S1). This observation suggests that the
dystrophin-negative (utrophin-positive) fibers of 10–30% WT/mdx
muscle are stabilized, perhaps by the presence of the neighboring
dystrophin-positive fibers or other dystrophin-positive tissues outside
of the muscle. In support of the notion that correction of the skeletal
muscle occurs as a whole, we found that while the slow isoform of
MHC (sMHC) was grouped in clusters in the mdx diaphragm
(Fig. 8b, compare to Fig. 8a), sMHC was restored to a normal
pattern in the diaphragm of the 10–30% WT/mdx mice (Fig. 8c, d),
in areas of high dystrophin (Fig. 8c, inset) and also in areas with low
dystrophin (Fig. 8d, inset). Dystrobrevin-a localized to the
sarcolemma of 10–30% WT/mdx muscle (Fig. 9e–h and Table 1),
in areas with high dystrophin (Fig. 9e, f) and also in areas with low
dystrophin (Fig. 9g, h). In western blots performed with 10–30%
WT/mdx muscles (Fig. 10, lane 2), a major isoform of dystrobrevin-
a of about 40 kD was detected at high levels. Other isoforms of
dystrobrevin-aweredetected.Variationsinthe molecularweight are
apparent between some mdx and WT isoforms of dystrobrevin, with
Figure 4. Embryonic MHC (eMHC) is greatly reduced in the
skeletal muscle of R26 WT/mdx chimeras. a–d, diaphragms from
WT (a), mdx+/2 (a, inset), 10–30% WT/mdx (b–d), 5–10% WT/mdx (e, f),
,5% WT/mdx (g) and mdx (h) mice were sectioned and stained for
dystrophin (green) and eMHC (red). b–d, areas with high (b) and low (c,
d) numbers of dystrophin-positive fibers within the same WT/mdx
diaphragm. e, f, all areas within the 5–10% WT/mdx diaphragm display
low numbers of dystrophin-positive fibers. DAPI (blue) demarcates
nuclei. Magnification: 2006. eMHC detection experiments were
performed with pectoralis, diaphragm and quadriceps muscles of 2–4
animals per group (WT [n=4], mdx+/2 [n=2], 10–30% WT/mdx [n=4],
5–10% WT/mdx [n=2], ,5% WT/mdx [n=4] and mdx [n=3]).
doi:10.1371/journal.pone.0004759.g004
ESC Corrections in Mdx Mice
PLoS ONE | www.plosone.org 6 March 2009 | Volume 4 | Issue 3 | e4759the chimeric samples containing both types (Fig. 10, lane 2, compare
to lanes 1 and 3). The 40 kD isoform observed in the chimeras is an
isoform observed predominantly in the WT sample (Fig. 10, lane 1).
Thus, the levels of the 40 kD isoform of dystrobrevin correlate with
the levels of full-length dystrophin. Similarly, nNOS was predom-
inantlydetectedintheWTandinthechimeras(Fig.10andTable1).
Thus, nNOS levels correlate with dystrophin levels as well.
Syntrophin levels however are not sensitive to dystrophin levels,
since it was detected also in the western blot with an mdx sample
(Fig. 10). However, immunodetection using the same antibody failed
to localize syntrophin to the sarcolemma of the mdx muscle (Fig. 11
and Table 1). It is possible that in the absence of dystrophin,
syntrophin fails to attach to the sarcolemma but is not destroyed.
WT/mdx mice display corrections outside the skeletal
muscle fibers
Within the muscle, corrections outside the skeletal fiber proper
were also apparent. Myelin basic protein (MBP), a major
component of the Schwann cells, was downregulated in the mdx
muscle (Table S1: 4.29-fold decrease, mdx vs WT) whereas MBP
levels in the 10–30% WT/mdx chimeric muscle were restored to
normal (Table S2: unchanged, WT/mdx vs WT). Schwann
processes, which guide the innervation of a newly regenerated
fiber, are compromised in the mdx muscle [38]. Corrections
outside the skeletal fibers were also apparent. Unlike mdx, which
are lean, WT/mdx chimeric mice with 10–30% WT ESC
chimerism had improved fat mass (abdominal fat weight/total
weight of WTs: 4.261.5%, of mdx mice: 1.260.4%, of 10–30%
WT/mdx chimeras: 4.061.4%) (P,0.05). The nearly 4-fold
increase in the mass of the chimeric adipose tissue (relative to
mdx adipose tissue) is proportional to the number of adipocytes, as
both the mdx and the WT/mdx chimeric fat cells have
comparable cell size (data not shown). To determine the molecular
consequences of the incorporation of WT ESCs into the mdx fat,
gene expression profiles were investigated. The mdx and the 10–
30% WT/mdx chimeric fat displayed upregulation of several
skeletal and cardiac muscle contractile genes (relative to WT
fat)(Tables 3, S3 and S4). Among these markers were myosin,
actin, tropomyosin and troponin isoforms (Table 3). Interestingly,
follistatin-like, a secreted factor that binds and antagonizes the
effect of myostatin and promotes muscle hypertrophy [39], was
also upregulated in the mdx and the WT/mdx fat (13.93- and
Figure 5. WT/mdx chimeric muscle is composed of dystrophin-positive (utrophin-negative) and dystrophin-negative (utrophin-
positive) fibers. a–l, diaphragms from WT (a–c), mdx (d–f) and 10–30% WT/mdx chimeric (g–l) mice were sectioned and stained for dystrophin
(a,d,g,j) and utrophin (b,e,h,k). (c,f,i,l): dystrophin (green)/utrophin (red) overlay. Note absence of yellow (overlay of green and red), indicating no
dystrophin/utrophin co-localization. g–i, areas of high dystrophin; j–l, areas of low dystrophin in the diaphragm of the same mouse. Magnification:
2006. Experiments were performed with pectoralis and diaphragm muscles of 3 animals (n=3) per group (WT, 10–30% WT/mdx and mdx).
doi:10.1371/journal.pone.0004759.g005
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The presence of follistatin-like 1 and 3, but not of follistatin, was
confirmed in the 10–30% chimeric fat by RT-PCR (data not
shown). Taken all together, these experiments suggest that WT
ESCs injected into mdx blastocysts result in changes in non-muscle
tissues like the fat. As a consequence of chimerism, the adipose
tissue increases mass and upregulates muscle contractile genes and
paracrine bioactive genes.
Dystrophin from WT ESC-derived muscle is required to
correct muscular dystrophy
To determine if the rescue is dependent on the percentage of
WT ESCs incorporated into the muscle syncytium also at the
molecular level, we examined gene expression profiles with RNA
from ,5% chimeric muscle. Unlike the muscle from 10–30%
chimeric mice (which showed reversion of dystrophic markers,
Tables 2 and S2), microarray analysis from the ,5% chimeric
muscle showed no reversion (relative to WT: 6.5-fold decrease for
dystrophin, 32-fold increase for embryonic myosin heavy poly-
peptide, 6.96-fold increase for thymosin-b10 and 4 procollagen
genes increased). This suggests that the degree of molecular
corrections depends on the number of WT ESCs incorporated and
confirms our previous observations indicating that a minimal
incorporation of ESCs (less than 5%) is insufficient to effect
histological and functional corrections in the mdx musculature. To
determine if dystrophin from the ESCs is required to effect
corrections, we derived LacZ-marked ESC clones from mdx mice
(Table 4). Two such mdx ESC clones with normal karyotypes
(HE5 and HA4) were injected into mdx blastocysts to create
chimeras with ESC-derived tissue without dystrophin (mdx/mdx
chimeras, n=7). A broad range of mdx/mdx chimeras examined
(0–70% of mdx ESC incorporation) showed a dystrophic
phenotype (Fig. 12e, f), with no correction of gene expression
profiles (Tables 2 and S5). MBP failed to be normalized in the
mdx/mdx muscle (Table S5: mdx/mdx vs WT: 2.0 fold-decrease
for MBP). The fat mass phenotype also failed to be corrected by
mdx ESC injection (abdominal fat weight/total weight:
0.960.2%, compare with WT/mdx chimeras: 4.061.4%,
P,0.05). Thus, dystrophin from the ESCs is required to correct
muscular dystrophy globally.
Discussion
Studies determining the minimal amount of dystrophin and the
minimal number of skeletal fibers that need to express dystrophin
in the skeletal muscle to correct or ameliorate disease have been
performed previously [3,4,27]. Lack of pathology has been
described in mosaic mice with roughly 50% of the fibers
expressing dystrophin [3,27]. Hearts from aging mdx heterozy-
gous mice, which express dystrophin in 50% of the cardiomyo-
cytes, unlike those from mdx mice, do not develop cardiomyop-
athy [40]. Introduction of transgenic dystrophin in mdx mice
corrects disease when the muscle expresses more than 20% of the
total dystrophin protein [3]. It appears therefore that only a
fraction of the numbers of fibers and of the total amount of
dystrophin is critical for disease correction.
Previously we described that WT ESCs rescue the lethality of Id
knockout embryos, a mouse model of the thin myocardial
syndrome, and that ESC-derived secretion factors accounted for
the reversion of the phenotypes in the embryonic heart and brain
[41–43]. Here we show that although dystrophin is a key structural
protein, low numbers of WT ESCs (10–30% chimerism)
incorporated into mdx mice prevent disease at the morphological
and functional level. Surprisingly, rather than containing 10–30%
of dystrophin levels, we found that the mosaic muscle contained
higher levels of dystrophin, in some cases comparable to wild-type.
We also found a tight correlation between levels of dystrophin
(western blot) and percentage of fibers expressing dystrophin
(immunofluorescence) or b-galactosidase (Xgal staining). Limb
(quadriceps) and thoracic (pectoralis) muscles exhibited the highest
levels of dystrophin protein and the highest levels of Xgal staining,
while the diaphragm had lower levels of dystrophin protein and
lower levels of Xgal staining (but higher levels than other tissues
that do not syncitialize, like heart). Despite differences in levels, all
muscles with 10–30% of incorporation showed improvement of
pathology. We determined that b-gal expansion in the skeletal
muscle does not require the presence of an mdx component, as is
also observed in WT/WT chimeras. Likewise, b-gal expansion
occurs during development, since we have observed this
phenomenon in the musculature before birth. b-gal expansion
correlates with multinucleation, as it is observed only at late stages
of development (when multinucleation is apparent) but not at
midgestation (when multinucleation is not apparent). Despite b-gal
expansion and an increase in dystrophin protein in the mosaic
muscle, the degree of chimerism is low, as it contains only one-fifth
of WT ESC-derived myonuclei. Since the degree of chimerism in
these muscles is low the net increase in dystrophin production may
be due to enhanced production, and/or perhaps, decreased
destruction. The effect of overproduction is not because the WT
component is derived from ESCs, as mdx+/2 skeletal muscle
(which does not contain ESC-derived myonuclei) also shows WT
levels of dystrophin (despite that 50% of the myonuclei expresses
dystrophin). However, this effect of overproduction and spatial
expansion is specific for the multinucleated skeletal muscle, as
neither heterozygous nor chimeric hearts overproduce dystrophin.
Skeletal muscle has the distinct property to regenerate via
activation of satellite cells. In this regard, we have observed that
blastocyst injection of ESCs also results in mosaicism of the
myogenic cell population, and that this population is capable of
producing Xgal posititve, multinucleated myotubes. Thus, the
chimeric pool of myogenic cells could be responsible for
regenerating the muscle with new fibers containing ESC-derived
Figure 6. Dystrophin is detected in cardiomyocytes in the WT/
mdx chimeric heart. Dystrophin immunofluorescence (green) was
performed on sections of WT (a), mdx+/2 (b), 10–30% WT/mdx
chimeric (c) and mdx (d) heart (4006). Note the presence of revertant
cardiomyocytes in (d, bottom right). DAPI (blue) demarcates nuclei.
Experiments were performed with 3 animals (n=3) per group (WT,
mdx+/2, 10–30% WT/mdx and mdx).
doi:10.1371/journal.pone.0004759.g006
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dystrophin. The rescue by WT ESCs is dose-dependent, as WT/
mdx mice containing less than 5% of WT chimerism do not
exhibit improvement of pathology or function. Patches in the
skeletal muscle of 10–30% WT/mdx chimeras contained little
dystrophin. However, even these areas displayed an improvement
of the pathology. Dystrobrevin, a member of the DGC [18,20],
which is a dystrophin-related protein, is stabilized in the fibers
containing minimal dystrophin, but fibers devoid (with undetect-
able levels) of dystrophin do not display dystrobrevin. Thus, a
minimal amount of dystrophin is required for co-localization of
dystrobrevin to the sarcolemma. Utrophin, another dystrophin-
related protein, is present in WT/mdx fibers with negligible
dystrophin, but unlike dystrobrevin, utrophin is normally present
in the sarcolemma of the mdx fibers. Little regeneration occurs in
these fibers, suggesting that there is little degeneration and that the
DGC is assembled and functional. Dystrobrevin can potentially
replace some functions of dystrophin especially those associated
with the binding of syntrophin and through it to nNOS [16,44],
but recent experiments show that forced expression of a functional
dystrobrevin isoform to the sarcolemma does not ameliorate
disease in the mdx mice [16]. Thus, a minimal presence of
Figure 7. WT/mdx chimeric muscle overproduces dystrophin. a, c, e and f, protein extracts from hearts (a), pectoralis (c), quadriceps (e) and
diaphragms (f) of WT, 10–30% WT/mdx, 5–10% WT/mdx and ,5% WT/mdx mice were subjected to a western blot for dystrophin and tubulin (load
control). Band intensities (dystrophin/tubulin) were scanned and values relative to WT (100%) are presented in Table I. b, d, protein extracts from
hearts (b) or pectoralis muscles (d) of WT, mdx+/2 and mdx mice were subjected to a western blot for dystrophin and tubulin. Western blots were
performed with extracts of hearts and various muscles (pectoralis, quadriceps and diaphragm) from 2–4 animals per group (WT [n=3], mdx+/2
[n=2], 10–30% [n=4], 5–10% [n=2], ,5% [n=4] and mdx [n=3]). g, DNA from 10–30% (n=4) R26 WT/mdx, R26 WT (n=2) and non-R26 WT (n=3)
mice were isolated from quadriceps muscles and subjected to semi-quantitative PCR using primers for LacZ or GAPDH. Note in that the 10–30%
quadriceps muscle shows normal levels of dystrophin (relative to WT) (e) but only a fraction of LacZ-positive DNA (relative to R26 WT) (g).
doi:10.1371/journal.pone.0004759.g007
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mdx chimeras) appears to be critical to improve the pathology.
The muscle is not the sole target of the ESC-derived dystrophin,
as the chimeras also display increased fat mass. The increase in cell
mass is not due to an increase in cell size, as the chimeric adipocyte
size is not enlarged. Unlike the muscle, the adipose tissue does not
express full-length dystrophin. Although the fat does not express
dystrophin, the rescue depends on dystrophin, as mdx ESCs
without dystrophin fail to revert the fat phenotype. This suggests
that there are dystrophin-expressing tissues involved in the rescue
of the mass of the adipose tissue, and supports the notion of
mechanisms of communication between tissues, in this case fat and
non-fat tissues. It is possible that the primary dystrophin-positive
Table 2. Markers of muscular dystrophy are reversed in WT/mdx but not in mdx/mdx muscle.
name accession number fold change
mdx vs WT WT/mdx vs WT mdx/mdx vs WT
dystrophin, DMD 1448665_at 27.46 unchanged 22.3
myosin, heavy polypeptide
3, embryonic 1427115_at 24.25 unchanged 147
thymosin b10 1436902_x_at 4.29 unchanged 4.29
procollagen type I, a2 1423110_at 6.06 2.14 4.92
procollagen type III, a1 1427884_at 2 unchanged 5.28
doi:10.1371/journal.pone.0004759.t002
Figure 8. Slow MHC is not clustered in the skeletal muscle of
WT/mdx chimeric mice. a–d, diaphragms from WT (a), mdx (b) and
10–30% WT/mdx chimeric (c, d) mice were sectioned and stained for
slow MHC (green). c and d, insets, adjacent sections of (c) and (d)
respectively from the same diaphragm stained for dystrophin. DAPI
(blue) demarcates nuclei. Magnification: 2006. Experiments were
performed with diaphragm muscles of 2 animals (n=2) per group
(WT, mdx and 10–30% WT/mdx).
doi:10.1371/journal.pone.0004759.g008
Figure 9. Dystrobrevin is present in areas with low dystrophin
in WT/mdx muscle. a–h, diaphragms from WT (a, b), mdx (c, d), and
10–30% WT/mdx (e–h) were sectioned and stained for dystrophin (a, c,
e, g) and dystrobrevin (b, d, f, h). e–h, areas with high dystrophin (e, f)
and areas with low dystrophin (g, h) within the same muscle.
Magnification: 2006. Experiments were performed with pectoralis and
diaphragm muscles of 3 animals (n=3) per group (WT, mdx and 10–
30% WT/mdx).
doi:10.1371/journal.pone.0004759.g009
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normalization of the muscle phenotype, other tissues like the fat
are normalized. It is also possible that other dystrophin-positive
tissues (e.g. neuronal, smooth muscle, heart) play corrective roles.
But what could be the reciprocal effect of the recovered chimeric
fat mass on the state of the rescued muscle? The fat tissue is a rich
source of circulating bioactive factors that may act in a paracrine
manner [45]. In a dystrophic muscle, the adipose tissue replaces
necrotic areas [46]. Thus, fat and muscle are intimately related.
Indeed, brown fat cells arise from precursors that express Myf5, a
gene previously thought to be expressed only in the myogenic
lineage, and muscle/fat inter-conversion can be bi-direcionally
achieved by manipulating key switch transcriptional regulators
[47]. In this regard, we noticed that a set of muscle contractile
proteins (cardiac and skeletal myosin, tropomyosin and troponin
isoforms) is differentially upregulated in the mdx fat (relative to the
WT fat). This enriched pattern of ‘‘muscularized’’ fat is also
apparent in the chimeric fat. Along with changes in contractile
markers, a set of growth/hypertrophic factors is altered in the
chimeric fat. For example, follistatin-like is upregulated in both the
mdx and chimeric fat (relative to WT). Follistatin and follistatin-like
are circulating factors that bind and antagonize myostatin,
promoting hypertrophy in the skeletal muscle [39,48,49], and the
muscle of the WT/mdx chimeric mice shows signs of hypertrophy
(our study). In addition to follistatin-like, other families of secreted
factors are altered in the chimeric fat, like insulin-like growth factor
(IGF), its binding proteins (IGFBP) and Wnts (unpublished data).
Thus, the presence of increased adipose mass coupled with the
presence of upregulated key growth/hypertrophic factors observed
in the chimeric fat makes this tissue a candidate source of bioactive
signals. These paracrine signals may have an impact on the growth/
hypertrophic state of a muscle that has only a fraction of dystrophin,
like WT/mdx muscle. Whether the changes observed in the
chimeric fat play a role in the corrections of the chimeric
musculature, particularly in the fibers that have negligible levels of
dystrophin, itremains tobe determined.It isnoteworthy topoint out
that DMD patients undergo a biphasic mode of fat gain/loss with an
increaseinfatmassintheprepubertalagefollowedbyadeclineinfat
mass after 13 years of age. It is important for such patients to
maintain their body weight to prevent the deterioration of
respiratory function and to prolong their life [50]. Importantly,
our results suggest that ESC-derived dystrophin is required for the
global corrections observed in the chimeric mice.
Materials and Methods
Embryonic stem cells
WT LacZ-marked R26 embryonic stem cells were developed
and provided by Phillipe Soriano. WT R26 cells grow in DMEM
with high glucose, 15% FCS, glutamine, nonessential aminoacids,
Figure 10. WT/mdx muscle displays nNOS and dystrobrevin-a.
Protein extracts from diaphragms ofWT (lane 1), 10–30% WT/mdx (lane2)
and mdx (lane 3) mice were subjected to a western blot for dystrophin,
nNOS, dystrobrevin-a, syntrophin and tubulin. *: dystrobrevin-a isoforms
enriched in mdx and WT/mdx but not in WT muscle. Experiments were
performed with pectoralis, diaphragm and quadriceps muscles of 3
animals (n=3) per group (WT, 10–30% WT/mdx and mdx).
doi:10.1371/journal.pone.0004759.g010
Figure 11. Syntrophin is present in WT/mdx but not in the mdx
muscle. a–f, diaphragms from WT (a, b), mdx (c, d), and 10–30% WT/
mdx (e–f) mice were sectioned and stained for dystrophin (a, c, e) and
syntrophin (b, d, f). Magnification: 2006. Experiments were performed
with diaphragms of 2 animals (n=2) per group (WT, mdx and 10–30%
WT/mdx).
doi:10.1371/journal.pone.0004759.g011
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which constitutively express LIF.
Mouse colonies
Hemizygous C57BL/10ScSn-mdx/J (mdx for muscular dystro-
phy gene localized to the X-chromosome) males and homozygous
C57BL/10ScSn-mdx/J (mdx) females were purchased from
Jackson lab. The colony was maintained by crossing mdx males
with mdx females. To generate mdx+/2 females, WT males
(C57BL/10) were crossed with mdx females. Male WT or mdx
mice, and female mdx+/2 mice were analyzed. All animal
experiments were approved by the Institutional Animal Care and
Use Committee (IACUC) of the University of Medicine and
Dentistry of New Jersey.
Establishment of mdx, LacZ-marked ESCs
Hybrid mdx/Y:R26/+ males were generated by mating R26
males with C57BL/10ScSn-mdx/J females and selecting for
progeny carrying both the R26 allele and mdx mutation. Four
weeks old C57BL/10ScSn-mdx/J females purchased from Jax labs
were superovulated (12 females) and mated with mdx/Y:R26/+
hybrid males. Mated females were checked for plugs the next
morning to identify successfully mated animals.
ES cells were established using a modified version of the method
described by Andras Nagy et al. (Manipulating the Mouse
Embryo, 3rd ed, CSHL Press). Plugged females were euthanized
3 days after mating and uterine horns were flushed with M2
medium to retrieve blastocysts as well as late morula stage
embryos. Flushed embryos were maintained at 37uC in 5% CO2
in micro-drops of M16 medium under oil for 2 days to allow
hatching from the zona. After this incubation, hatched blastocysts
were transferred individually into wells of a 96-well plate,
containing mouse embryo fibroblasts (MEF) as feeders and
cultured in ESC medium (DMEM with high glucose, supplement-
ed with 15% FCS, 0.1 mM b-mercaptoethanol, 4 mM L-
glutamine, 16 Non-essential amino acids and 1000 U/ml LIF)
until outgrowths of the inner cell mass (ICM) are evident. Healthy
ICM outgrowths were disaggregated between day 7 and 8, and
plated onto fresh feeder cells. Cultures were monitored for ES cell
colonies and all healthy colonies were passaged and expanded to
establish ES lines. A total of 20 ES cell lines were obtained. Of
these, thirteen were analyzed for AP and lacZ activities and their
karyotype examined.
Analysis of the established ES cell lines
Alkaline Phosphatase (AP) activity. The ES clones were
cultured on 24-well gelatin-coated dishes without feeders until
confluency. Cells were rinsed twice with PBS, fixed with 4% para-
formaldehyde at room temperature for 15 minutes, and then
rinsed with PBS. Fixed cell samples were tested for AP activity by
incubating with substrate (5 mg Sodium alpha-naphthyl
phosphate, 5 ml 5% borax, 44.6 ml H2O, 0.3 ml 10% MgCl2,
12 mg Fast Red TR, PH to 9.2) at 37uC for 30 minutes. After
incubation, cells were rinsed and examined for AP staining.
Karyotype Analysis. The ES clones were cultured in 6-well
plates coated with gelatin without feeders and grown to about 70%
confluency. Cells were then karyotyped by the MSKCC Molecular
Cytogenetics Core Facility.
Table 3. Cardiac and skeletal muscle contractile markers are upregulated in mdx and WT/mdx adipose tissue.
name accession number fold change
mdx vs WT WT/mdx vs WT
Actin, a1, skeletal muscle 1427768_s_at UC 8.57
MyHC, fast skeletal muscle embryonic 1428655_at 24.92 UC
MyHCa cardiac 1448826_at 147.03 UC
MyHC-IIX 1427520_a_at UC 55.72
MyHC-IIB 1427026_at 16 48.5
MyH polypeptide 7, cardiac muscle b 1448554_s_at 16 UC
MyLC-alkali fast skeletal 1452651_a_at UC 24.25
MyLC ventricular alkali 1427768_s_at 13.93 UC
MyLC phosphorylatable cardiac ventricles 1448394_at 4.59 4.29
Myosin X 1450650_at 4.59 4
Myosin 1B 1448989_a_at UC 2.3
Myosin Vb 1452298_a_at UC 2.14
Myosin Va 1431320_a_at 22.83 UC
Tropomyosin-2b 1425028_a_at 3.73 17.15
Tropomyosin 3c (non-muscle) 1427567_a_at UC 213
Tropomyosin-1a 1423049_a_at 17.15 25.99
Troponin C fast skeletal 1417464_at 32 97.01
Troponin T2 cardiac 1418726_a_at 36.76 24.25
Troponin T cardiac, isoform A2b 1424967_x_at 24.25 16
Troponin T3, skeletal fast 1450118_a_at UC 6.5
Troponin C cardiac slow skeletal 1418370_at 6.5 3.73
Troponin I, cardiac 1422536_at 3.48 3.73
doi:10.1371/journal.pone.0004759.t003
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the R26 b-gal gene trap allele, ES cells were grown in gelatin-
coated 24-well plates until confluency. Cells were rinsed twice with
PBS, then once with buffer A (10 mM Na-Phosphate, PH 7,
150 mM NaCl, 1 mM MgCl2). Samples were fixed with 1%
glutaraldehyde in buffer A for 5 minutes at room temperature.
After fixing, cells were rinsed with buffer B (3.3 mM K3Fe(CN)6,
3.3 mM K4Fe(CN)6N3H2O in buffer A), and then tested for b-gal
activity by incubating with the substrate X-gal (0.3% X-Gal in
buffer B) at 37uC in dark for 3 hours. Samples were rinsed and
either examined immediately for stained cells or kept in PBS at
4uC, in the dark, until ready for analysis.
Generation of chimeric mice
3-week old mdx (C57BL/10ScSn-Dmd
mdx/J, Jax labs) females
were superovulated and mated with mdx males (Jax labs).
Blastocysts were collected at 3.5 days afer mating, injected with
either 15 WT R26 or 15 mdx R26 ES cells. Injected blastocysts
were then transferred into the uteri of pseudopregnant females and
allowed to develop to term. A combination of X-gal staining/eosin
counterstaining on tail tip cryosections at 1 week of age, on liver,
heart or lung cryosections at 4 months of age, semi quantitative
PCR of the LacZ transgene (liver, muscle) and dystrophin
immunofluorescence on heart cryosections (in case of WT/mdx
chimeras at 4 months of age was used to characterize percentage
of ESC incorporation. All chimeric animals analyzed were males.
Immunofluorescence (IMF), X-gal histochemistry, western
blot (WB)
Diaphragms, pectoralis, quadriceps and hearts were collected at
4 months of age, OCT embedded and cryosectioned (12 mm).
Antibodies reactive with dystrophin (dys2 for IMF and dys1 for
WB, Novocastra), utrophin (generously provided by Dr. Fritschy,
University of Zurich), dystrobrevin-a (610766, BD Transduction
Laboratories), syntrophin (MA1-745, ABR), neuronal nitric oxide
synthase (PA1-038, ABR), sarcoglycan b (Novocastra), embryonic
myosin heavy chain F1.652 (Developmental Studies Hybridoma
Bank, DSHB) slow myosin heavy chain (MHCs, Novocastra) were
used. Before OCT embedding, hearts were placed in Krebs-
Ringer solution to allow arrest in diastole. X-gal staining was
performed on sections with X-gal (1 mg/ml) in PBS buffer
containing 5 mM potassium ferricyanide, 5 mM potassium
ferrocyanide and 2 mM MgCl2 overnight at 37uC. Embryos were
either whole mount X-gal stained and subsequently cryosectioned
Figure 12. Mdx muscle receiving ESCs without dystrophin is
dystrophic. a–f, diaphragms from WT (a, b), mdx (c, d) and R26 mdx/
mdx chimeric (e, f) mice were sectioned and stained for dystrophin
(green) and utrophin (red) (a, c, e) and for eMHC (b, d, f). DAPI (blue)
demarcates nuclei (2006). g, Xgal/eosin staining of an adjacent section
of (e, f) (1006). Experiments were performed with pectoralis, diaphragm
and quadriceps muscles of 4 animals (n=4) per group (WT, mdx and
R26 mdx/mdx chimeras).
doi:10.1371/journal.pone.0004759.g012
Table 4. LacZ, alkaline phosphatase and karyotype analysis of the mdx ESC clones.
Clone LacZ AP Karyotype
HE5* + 60% + a predominantly normal male. A minor population lacks a Y chromosome.
A1-D4 + 90% + The majority of cells have trisomy 12, male.
A2-B4 + 70% +
GB3 + 90% + predominantly normal female An elevated level of tetraploidy is present.
HG1 + 70% +
HA4* + 65% + normal male
FA3 + 90% + a mixture of cells of different origin.
A1-C3b + 70% +
GE4 2 90% + stable triploid karyotype, 59–60,XXY [cp12]
A3-B6 2 95% +
GD2 2
CC3 + basically female mouse karyotype, though with an elevated level of tetraploidy and a population with only one X
chromosome
CC2 + The majority of cells were near tetraploid female with clonal aneuploidies
*HA4 and HE5 clones were used for blastocyst injection.
doi:10.1371/journal.pone.0004759.t004
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(E17.5). Myogenin F5D (Developmental Studies Hybridoma
Bank, DSHB) or Myosin Heavy Chain MF20 (DSHB) antibodies
were used to detect myogenic areas in E11.5 or E17.5 respectively.
In the case of whole mount staining at E11.5, the X-gal wash
buffer contained 0.02% Nonidet P-40. X-gal stained sections were
eosin counterstained before mounting. For western blot, a 4–20%
gradient acrylamide gel was used. High molecular weight protein
standards (HiMark, Invitrogen and Precision Plus, Biolab) were
used. The intensities of the WB exposures were quantified using
Quantity One software on a GS800-Densitometer (Bio-Rad). The
relative expression levels for the dystrophin bands were normal-
ized using tubulin bands within the same linear range of detection.
The muscle area collected for WB was not previously stained (Xgal
or dystrophin IMF), and since the ESCs distribute non-uniformly
in the muscle with intermingled areas of high and low dystrophin,
the protein extracts contained varying combinations of both high
and low dystrohin components. Because there were more areas
with high dystrophin than with low dystrophin in most of the 10–
30% muscles (i.e. pectoralis and quadriceps), the values obtained
in the WB were higher than 60% (see Table I).
Percentage of dystrophin-positive fibers (or
cardiomyocytes) and of X-gal positive fibers (or cells)
The number of dystrophin- and utrophin-positive cardiomyocytes
(or skeletal muscle fibers) was counted under a fluorescent
microscope (2006, 20 fields). To calculate the percentage of
dystrophin-positive cells (or fibers), the number of dystrophin-
positive cells (or fibers) was divided by the total number of cells (or
fibers) (dystrophin- plus utrophin-positive cells or fibers). Very rarely
a fiber contained dystrophin and utrophin staining, and it was
counted as dystrophin-positive if it contained more than 50% of
sarcolemma staining. The number of X-gal positive cells (or fibers)
and eosin positive liver, lung or cardiac cells (or skeletal fibers) was
counted under a bright microscope (2006, 20 fields). In most cases
the fibers stained dark blue, but in some cases fibers were light blue.
Dark and light blue fibers were counted as X-gal positive. To
calculate the percentageofX-gal positivecells (or fibers), thenumber
of X-gal positive cells (or fibers) was divided by the total number of
cells (or fibers) (X-gal positive plus eosin positive cells orfibers). X-gal
stained sections were also counterstained with light hematoxylin (for
nuclei visualization) when eosinalonedid not demarcate celllimitsin
the liver, heart or in the lung.
Semi quantitative genomic PCR
Genomic DNA from 4 chimeras was isolated from LacZ+ R26
WT/mdx, LacZ+ R26 mouse and LacZ- WT mouse skeletal
mouse tissue (quadriceps) by overnight digestion in SDS/
Proteinase K buffer followed by phenol/chloroform extraction.
50 ng of genomic DNA were used in PCR with Jackson Labs’
primers for genotyping the LacZ transgene incorporated in the
R26 locus (Jackson Labs IMR0092-AATCCATCTTGTTCAA-
TGGCCGATC&IMR3449-CCGGATTGATGGTAGTGGTC).
2 ng of the same DNA were used in PCR with G3PDH primers
(Clontech) for internal control. PCR was performed with puRe-
Taq Ready-To-Go PCR beads (GE Healthcare) for 31 and 35
cycles in the log phase. Scans were performed on Typhoon 8600
Variable Mode Imager (Molecular Dynamics), and quantitation
done using ImageQuant.
Functional analysis
Mice aged ,8 weeks with 10–30% (n=2) and ,5% (n=2) of
ESC chimerism and WT (n=4) and mdx (n=3) controls were
deeply anesthetized (2 mg xylazine-20 mg ketamine/100 g body
mass ip). Both fast-twitch extensor digitorum longus (EDL) muscles
were excised and incubated at 30uC in an oxygenated (95% O2-
5% CO2) physiological salt solution (PSS; pH 7.6) containing (in
mM) 120.5 NaCl, 4.8 KCl, 1.2 MgSO4, 20.4 NaHCO3, 1.6
CaCl2, 1.2 NaH2PO4, 10.0 dextrose, and 1.0 pyruvate. Silk suture
(4-O) was tied to the distal and proximal tendons of the EDL at the
myotendinous junctions. Muscles were then fixed between a clamp
at the base of the bath and arm of a dual-mode servomotor system
(300B, Aurora Scientific), or an isometric force transducer (Grass
FT03), at a resting tension (L0) of 1.0 g. EDL muscles were
maintained at L0 by a stepper motor [51]. The servomotor arm,
stepper motor and electrical stimulator were controlled by
Dynamic Muscle Control software (DMC Version 4.1.6, Aurora
Scientific) to obtain isometric force data. Isometric twitch and
tetanic data were obtained. Length of the muscles was obtained
with a micrometer; each muscle was weighed to the nearest
0.1 mg using an A-200D electronic analytical balance (Denver
Instruments, Denver, Colorado) and then muscles were snap
frozen in liquid nitrogen for subsequent sectioning and WB
analysis. Muscle cross-sectional area (CSA) was determined as
previously described [52]. Twitch and tetanic forces were
normalized to muscle CSA to obtain twitch and tetanic stress
(g/mm
2). As every muscle has a distinct pattern of ESC
incorporation in a chimera, the values obtained from the 2 EDL
muscles from the same animal (2 mice) were independently
considered, and thus, n=4 per chimeric category (10–30% and
,5%). The degree of chimerism was estimated by Xgal staining of
sections from tail biopsies, and further confirmed upon sacrifice by
Xgal and dystrophin (heart) and Xgal (liver) staining. Dystrophin
presence in the EDL muscles was confirmed by IMF and by WB.
Cross-sectional area measurements
Digitized images of diaphragm sections examined were
acquired using an upright microscope with camera driven by
diagnostic software. Image files were analyzed using ImageJ
software (NIH). Muscle fibers in cross-section were traced
onscreen using a mouse-driven cursor, and the dimensions of
highlighted fibers calculated within the software package based on
a calibrated screen pixel-to-actual size ratio [53].
Primary cell cultures
Myogenic cultures were prepared from R26 WT/mdx mice
according to an established protocol [54]. Cells were isolated from
diaphragm and quadriceps muscles after careful dissection of the
muscles to minimize connective tissue contribution. Collected
muscles, processed separately by source muscle, were enzymatically
digested sequentially by collagenase-1, dispase and trypsin. In
parallel, non-digested muscles were minced and cultured. Released
single cells (or minced explants) were cultured in gelatin-coated
plates in a serum-rich growth medium consisting of DMEM
supplemented with 25% fetal bovine serum (Hyclone, Logan, UT),
10% horse serum (Hyclone), 1% chicken embryo extract and
antibiotics. Cells were allowed to expand for up to two weeks and
subjected to differentiation into contracting myotubes for 5 days in
the presence of DMEM supplemented with 0.5% horse serum,
Myogenic cultures containing mononuclear cells and/or myotubes
were subsequently Xgal stained and photographed.
Microarray analysis
Total RNA from pectoralis muscle was isolated from a 4-month
old WT, mdx, WT/mdx or mdx/mdx mice (RNeasy, QIAGEN).
RNAwas converted to cDNA, cRNA, and hybridized to DNA
sequences contained in the MOEA2.0 (14,000 murine well-
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duplicate samples was compared and filtered by fold change.2
(mdx vs WT and WT/mdx vs WT) or by fold change.1.5 (mdx/
mdx vs WT) and statistical p-value,0.001. Data sets have been
deposited in Gene Expression Ommibus (GEO), with accession
number GSE12580.
Data analysis
Results are presented as mean6s.e.m or as a range. Statistical
comparison was performed with nonparametric two-tailed un-
paired analysis of variance. A probability value of ,0.05 was
considered to be statistically significant.
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